APPENDIX A:

Marked-up Version of Specification and Claims

In the Specification:

--This application is a divisional of co-pending application Serial No. 08/889,108 filed on July 7, 1997, now U.S. Patent No. 6,103,492, which is a divisional[file-wrapper continuation] of Serial No. 08/305,518 filed on September 13, 1994, now abandoned, which is a continuation in part[continuing application] of Serial No. 08/120,601 filed September 13, 1993, now U.S. Patent No. 6,235,496, which is a continuation in part[continuing application] of U.S. Serial No. 08/056,886 filed on March 8, 1993, now abandoned.—

In the claims:

83. A process of screening a candidate substance for its ability to bind to a mu opioid receptor comprising:

a) providing a recombinant mu opioid receptor polypeptide comprising the contiguous amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:8, or SEQ ID NO:17[;

b) obtaining a candidate substance]; and

b[c]) testing the ability of said candidate substance to bind to said opioid receptor.

85. The process of claim 83 wherein the step of testing the ability of the candidate substance to bind to the opioid receptor involves determining the [intrinsic activation] ability of the candidate substance [for]to activate the receptor.

86. A process for screening a candidate substance for its ability to bind to a mu opioid receptor comprising:

(a) providing a recombinant opioid receptor polypeptide encoded by a nucleic acid sequence comprising at least 35 contiguous nucleotides of SEQ ID NO:7, including the guanine nucleotide at position 389 of SEQ ID NO:7;

(b) contacting the candidate substance with the recombinant opioid receptor polypeptide; and

(c) detecting the ability of the candidate substance to bind to the recombinant opioid receptor polypeptide.

91. The process of claim 86, wherein the nucleic acid sequence comprises the nucleotide sequence of SEQ ID NO:7[, including the guanine nucleotide at position 389 of SEQ ID NO:7].

92. The process of claim 86, wherein detecting the ability of the candidate substance to bind to the recombinant opioid receptor polypeptide involves measuring (i) the ability of the recombinant opioid receptor polypeptide to bind the candidate substance; (ii) the ability of the candidate substance to activate ion channels in a cell membrane; or (iii) modulation of ion channels in the cell membrane of part (ii).

APPENDIX B:

Pending Claims (Unofficial)

83. (Amended) A process of screening a candidate substance for its ability to bind to a mu opioid receptor comprising:

a) providing a recombinant mu opioid receptor polypeptide comprising the contiguous amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:8, or SEQ ID NO:17; and

b) testing the ability of said candidate substance to bind to said opioid receptor.

84. The process of claim 83 wherein the step of testing the ability of the candidate substance to bind to the opioid receptor involves determining the binding affinity of the candidate substance to the receptor.

85. (Amended) The process of claim 83, wherein the step of testing the ability of the candidate substance to bind to the opioid receptor involves determining the ability of the candidate substance to activate the receptor.

86. (Amended) A process for screening a candidate substance for its ability to bind to a mu opioid receptor comprising:

(a) providing a recombinant opioid receptor polypeptide encoded by a nucleic acid sequence comprising at least 35 contiguous nucleotides of SEQ ID NO:7, including the guanine nucleotide at position 389 of SEQ ID NO:7;

(b) contacting the candidate substance with the recombinant opioid receptor polypeptide; and

(c) detecting the ability of the candidate substance to bind to the recombinant opioid receptor polypeptide.

87. The process of claim 86, wherein the nucleic acid sequence comprises at least 45 contiguous nucleotides of SEQ ID NO:7, including the guanine nucleotide at position 389 of SEQ ID NO:7.

88. The process of claim 86, wherein the nucleic acid sequence comprises at least 50 contiguous nucleotides of SEQ ID NO:7, including the guanine nucleotide at position 389 of SEQ ID NO:7.

89. The process of claim 86, wherein the nucleic acid sequence comprises at least 75 contiguous nucleotides of SEQ ID NO:7, including the guanine nucleotide at position 389 of SEQ ID NO:7.

90. The process of claim 86, wherein the nucleic acid sequence comprises at least 100 contiguous nucleotides of SEQ ID NO:7, including the guanine nucleotide at position 389 of SEQ ID NO:7.

91. (Amended) The process of claim 86, wherein the nucleic acid sequence comprises the nucleotide sequence of SEQ ID NO:7.

92. (Amended) The process of claim 86, wherein detecting the ability of the candidate substance to bind to the recombinant opioid receptor polypeptide involves measuring (i) the ability of the recombinant opioid receptor polypeptide to bind the candidate substance; (ii) the ability of the candidate substance to activate ion channels in a cell membrane; or (iii) modulation of ion channels in the cell membrane of part (ii).

93. The process of claim 86, wherein recombinant opioid receptor polypeptide is chimeric.

94. A process for screening a candidate substance for its ability to bind to an opioid receptor comprising:

(a) expressing a recombinant opioid receptor polypeptide encoded by a nucleic acid sequence comprising at least 35 contiguous bases of SEQ ID NO:7, including the guanine nucleotide at position 389 of SEQ ID NO:7;

(b) contacting the candidate substance with the recombinant opioid receptor polypeptide; and

(c) detecting the ability of the candidate substance to bind to the recombinant opioid receptor polypeptide.

95. The process of claim 94, wherein the nucleic acid sequence comprises at least 40 contiguous nucleotides of SEQ ID NO:7, including the guanine nucleotide at position 389 of SEQ ID NO:7.

96. The process of claim 94, wherein the nucleic acid sequence comprises at least 45 contiguous nucleotides of SEQ ID NO:7, including the guanine nucleotide at position 389 of SEQ ID NO:7.

97. The process of claim 94, wherein the nucleic acid sequence comprises at least 50 contiguous nucleotides of SEQ ID NO:7, including the guanine nucleotide at position 389 of SEQ ID NO:7.

98. The process of claim 94, wherein the nucleic acid sequence comprises at least 75 contiguous nucleotides of SEQ ID NO:7, including the guanine nucleotide at position 389 of SEQ ID NO:7.

99. The process of claim 94, wherein the nucleic acid sequence comprises at least 100 contiguous nucleotides of SEQ ID NO:7, including the guanine nucleotide at position 389 of SEQ ID NO:7.

100. The process of claim 94, wherein the nucleic acid sequence comprises the nucleotide sequence of SEQ ID NO:7, including the guanine nucleotide at position 389 of SEQ ID NO:7.

101. The process of claim 94, wherein recombinant opioid receptor polypeptide is chimeric.

APPENDIX C



WEBSTER'S NEW TWENTIETH CENTURY DICTIONARY OF THE ENGLISH LANGUAGE

UNABRIDGED

SECOND EDITION

BASED UPON THE BROAD FOUNDATIONS LAID DOWN BY

Noah Webster

EXTENSIVELY REVISED BY THE PUBLISHER'S EDITORIAL STAFF UNDER THE GENERAL SUPERVISION OF

JEAN L. McKECHNIE

INCLUDING ETYMOLOGIES, FULL PRONUNCIATIONS, SYNONYMS, AND AN ENCYCLOPEDIC SUPPLEMENT OF GEOGRAPHICAL AND BIOGRAPHICAL DATA, SCRIPTURE PROPER NAMES, FOREIGN WORDS AND PHRASES, PRACTICAL BUSINESS MATHEMATICS, ABBREVIATIONS, TABLES OF WEIGHTS AND MEASURES, SIGNS AND SYMBOLS, AND FORMS OF ADDRESS

ILLUSTRATED THROUGHOUT

SIMON AND SCHUSTER

OIPE
SEP 30 2002
PATENT & TRADEMARK OFFICE
RECEIVED
OCT 03 2002
TECH CENTER 1600/2900

WEBSTER'S NEW TWENTIETH CENTURY DICTIONARY

Second Edition

Copyright © 1983 and 1955, 1956, 1957, 1958, 1959, 1960, 1962, 1964,
1968, 1970, 1975, 1977, 1979 by Simon & Schuster, a Division of Gulf & Western Corporation
Full-Color Plates Copyright © 1972 by Simon & Schuster, a Division of Gulf & Western Corporation
All rights reserved
including the right of reproduction
in whole or in part in any form
Published by New World Dictionaries/Simon and Schuster
A Simon & Schuster Division of Gulf & Western Corporation
Simon & Schuster Building
Rockefeller Center
1230 Avenue of the Americas
New York, New York 10020
SIMON AND SCHUSTER, TREE OF KNOWLEDGE and colophon are trademarks
of Simon & Schuster.

Dictionary Editorial Offices
New World Dictionaries
850 Euclid Avenue
Cleveland, Ohio 44114

Manufactured in the United States of America

10 9 8 7 6

Library of Congress Catalog Card Number: 83-42537

ISBN 0-671-41819-X

Previous editions of this book were published by The World Publishing Company, William Collins +World Publishing Co., Inc. and William Collins Publishers, Inc.

PRINTED IN THE UNITED STATES OF AMERICA

RECEIVED
OCT 03 2002
TECH CENTER 1600/2900



in·trin'sic, *a.* [Fr. *intrinsèque*; ML. *intrinsicus*, from L. *intrinsecus*, on the inside, inwardly; *intra*, within, and *secus*, otherwise, beside.]

1. belonging to the real nature of a thing; not dependent on external circumstances; essential; inherent.

2. in anatomy, located within, or exclusively of, a part.

Opposed to *extrinsic*.

intrinsic energy; the energy or force latent in any mechanism or form of matter; actual present power.

Syn.—real, genuine, native, inward, internal, true.

p.963